Semaglutide + Placebo
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Alzheimers Disease
Conditions
Alzheimers Disease
Trial Timeline
Jun 20, 2023 → Sep 8, 2025
NCT ID
NCT05891496About Semaglutide + Placebo
Semaglutide + Placebo is a phase 3 stage product being developed by Novo Nordisk for Alzheimers Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05891496. Target conditions include Alzheimers Disease.
What happened to similar drugs?
0 of 4 similar drugs in Alzheimers Disease were approved
Approved (0) Terminated (1) Active (3)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06041217 | Phase 3 | Completed |
| NCT05726227 | Phase 3 | Active |
| NCT05891496 | Phase 3 | Completed |
| NCT05486065 | Phase 2 | Completed |
| NCT04889183 | Phase 3 | Completed |
| NCT04979130 | Approved | Completed |
| NCT04822181 | Phase 3 | Active |
| NCT03842202 | Phase 1 | Completed |
| NCT03548987 | Phase 3 | Completed |
| NCT03357380 | Phase 1 | Completed |
| NCT03086330 | Phase 3 | Completed |
| NCT02692716 | Phase 3 | Completed |
| NCT02970942 | Phase 2 | Completed |
| NCT02906930 | Phase 3 | Completed |
| NCT02827708 | Phase 3 | Completed |
| NCT02773381 | Phase 1 | Completed |
| NCT02557620 | Phase 1 | Completed |
| NCT02305381 | Phase 3 | Completed |
| NCT02212067 | Phase 1 | Completed |
| NCT02161588 | Phase 1 | Completed |
Competing Products
15 competing products in Alzheimers Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E2814 + Lecanemab + Matching Placebo (E2814) | Eisai | Phase 2/3 | 42 |
| Gantenerumab + Solanezumab + Matching Placebo (Gantenerumab) + Matching Placebo (Solanezumab) + Gantenerumab + E2814 + Lecanemab + Matching Placebo (E2814) | Eisai | Phase 2/3 | 42 |
| Gantenerumab + Solanezumab + Matching Placebo (Gantenerumab) + Matching Placebo (Solanezumab) | Eli Lilly | Phase 2/3 | 38 |
| Remternetug + Matching Placebo (Remternetug) | Eli Lilly | Phase 2/3 | 45 |
| Remternetug (SC) + Matching Placebo (Remternetug) | Eli Lilly | Phase 2/3 | 45 |
| CNP520 50mg + CNP520 15mg | Novartis | Phase 2/3 | 30 |
| CAD106 Immunotherapy + CNP520 | Novartis | Phase 2/3 | 30 |
| Trontinemab | Roche | Phase 3 | 47 |
| RO7126209 + Placebo | Roche | Phase 1 | 29 |
| RO7126209 + Placebo | Roche | Phase 1/2 | 36 |
| Gantenerumab | Roche | Phase 2/3 | 30 |
| Trontinemab | Roche | Phase 3 | 47 |
| Gantenerumab + Placebo | Roche | Phase 3 | 32 |
| X/T + X-EC + Placebo + Lecanemab 10 mg/kg | Bristol Myers Squibb | Phase 2 | 42 |
| buntanetap/posiphen + Placebo | Annovis Bio | Phase 3 | 37 |